Quanterix (QTRX) Stock Price
Quanterix Price
Revenue has compounded at 27.5% per year over the past 10 years to 138.65 M USD. Quanterix's net margin stands at -77.3%, down from -52.2% several years earlier. Analysts set a median price target of 3.00 USD, implying 2.0% above the current price. Of 8 analysts, 0 rate the stock a buy — an overall Hold consensus.
Quanterix stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Quanterix business model & stock analysis
Frequently asked questions about Quanterix
The business model of Quanterix Corp focuses on developing and commercializing ultra-sensitive biomarker detection systems. By leveraging their proprietary Simoa technology, the company aims to provide researchers and clinicians with the tools necessary to advance precision medicine and improve the detection and treatment of various diseases. Quanterix Corp's cutting-edge platforms enable the measurement of previously undetectable biomarkers, opening up new possibilities in diagnostics, drug development, and personalized healthcare. With their dedication to innovation and pushing the boundaries of detection, Quanterix Corp strives to make a significant impact in the field of life sciences and transform the way diseases are diagnosed and monitored.
Quanterix Corp is primarily active in the life sciences and diagnostics industries.
The main competitors of Quanterix Corp in the market are companies like Bio-Techne Corporation, Thermo Fisher Scientific Inc., Abbott Laboratories, and Merck KGaA.
Quanterix Corp is a renowned biotechnology company founded in 2007. With its headquarters in Billerica, Massachusetts, the company specializes in developing ultra-sensitive analysis platforms, known as Simoa, for studying and measuring various biomarkers in life sciences. Quanterix Corp has revolutionized the field of biomarker analysis by enabling detection at previously unattainable levels, enabling breakthroughs in diagnostics, precision medicine, and life sciences research. The company's unparalleled technology has attracted collaborations with prominent academic institutions, pharmaceutical companies, and clinical laboratories worldwide. Quanterix Corp's commitment to innovation and improving patient outcomes has positioned it as a leading player in the field of precision health.
Quanterix Corp has achieved several significant milestones since its inception. The company's groundbreaking Simoa technology has revolutionized the field of ultra-sensitive biomarker analysis, enabling researchers to detect and measure extremely low levels of proteins and biomarkers. Quanterix Corp has also developed a strong portfolio of diagnostic tests for various diseases and conditions, such as neurodegenerative diseases, oncology, and infectious diseases. Moreover, the company has received numerous accolades and recognitions for its innovative approach, including being named a Technology Pioneer by the World Economic Forum. Quanterix Corp continues to advance in its mission to improve healthcare outcomes through cutting-edge diagnostics and precision medicine.
Quanterix Corp is primarily present in the United States and Europe.
Quanterix Corp represents values of innovation, precision, and dedication to advancing science and healthcare. With a strong corporate philosophy focused on transforming medicine through their proprietary technology, they strive to revolutionize diagnostics and biomarker analysis. Quanterix Corp is committed to developing highly sensitive biomarker detection solutions that enable researchers and clinicians to detect diseases far earlier and more accurately than previously possible. Continuously pushing the boundaries of scientific knowledge, Quanterix Corp's pioneering approach has the potential to improve patient outcomes and revolutionize the way healthcare industry operates.
Analysts currently set an average price target of 3.00 USD for the Quanterix stock (median: 3.00 USD), implying +2.0 % versus the latest price. The consensus is based on 8 analyst ratings.
8 analysts currently rate the Quanterix stock: 0 recommend buying, 5 holding and 3 selling. For 2026, analysts expect Quanterix to generate revenue of 143.36 M USD and earnings per share of -2.04 USD.
Converted at the current exchange rate, the Quanterix share trades at 2.62 EUR (2.94 USD).
The Quanterix share (QTRX) is listed on 1 stock exchanges, including: NASDAQ (QTRX).
Quanterix Corp is a company that specializes in the development and sale of instruments and reagents for digital diagnostic applications. It is working on developing technologies that increase the accuracy and sensitivity of tests, enabling better disease diagnosis and monitoring. The company's business model is based on three main divisions: instruments, reagents, and services. They offer automated systems that can conduct biomarker analysis at the single-molecule level. The company also provides training and consulting services for the use of their instruments and reagents. They are known for their Simoa technology, which is used for disease diagnosis based on the measurement of biomarkers in blood. Quanterix Corp works closely with leading companies in the life science industry to integrate their technology into their products. Overall, the company is recognized as a key player in the field of digital diagnostics.
The expected revenue of Quanterix is 143.36 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Quanterix is -95.51 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Quanterix is currently -1.44. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Quanterix stock.
The price-to-sales ratio (P/S) of Quanterix is currently 0.96. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Quanterix stock.
The Eulerpool Quality Score for Quanterix is 5/10.
The ISIN of Quanterix is US74766Q1013. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Quanterix is A2H9FB. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Quanterix is QTRX. The ticker symbol is used to trade Quanterix shares on the stock exchange.
Quanterix stock
Quanterix Peer Group
Quanterix Ticker
Quanterix FIGI
All fundamentals and in-depth analysis of Quanterix
Our stock analysis for Quanterix stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Quanterix. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.